Arthrotec 75 · DIN 02229837 · 75 mg & 200 mcg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: RxHelp ONE lists Arthrotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Arthrotec 75 · DIN 02229837
Manufacturer: Pfizer Canada Inc.; listing date 1997-08-28
Health Canada: Marketed since 2006-01-12 · brand ARTHROTEC 75 · ATC M01AB55 DICLOFENAC, COMBINATIONS · form Tablet (delayed-release) · route Oral · ingredients DICLOFENAC SODIUM 75 MG, MISOPROSTOL 200 MCG · company Pfizer canada ulc · schedule Prescription
Ministry pays: $0.4286 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02229837)
Source record
DIN 02229837: Arthrotec 75
Raw flags: sec3=Y
Item: 280804056; group id 380; item number 0908; lccId None; manufacturer id PFI
Source form: Tab; strength: 75mg & 200mcg
Recorded listing: General benefit
Source prices (unrounded): $1.0599; ministry $0.4286
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02229837
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48191
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Gd-Diclofenac/Misoprostol 75 · DIN 02341697 · $0.4286
PMS-Diclofenac-Misoprostol · DIN 02413477 · $0.4286
Shortage status: not checked (no credentials)